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The solubility of diflunisal, a nonsteroidal anti-inflammatory drug (NSAID), in supercritical carbon dioxide
(scCO2) was measured at (308.2, 318.2, and 328.2) K and in the pressure range from (9.0 up to 25.0) MPa.
Results were obtained using a static analytical method. Experimental solubility was found to be between
0.54 ·10-6 and 8.07 ·10-6 (in terms of diflunisal mole fraction). Experimental data were satisfactorily
correlated with an equation-of-state (EOS) model: the Peng-Robinson cubic equation of state (PR-EOS)
together with the conventional van der Waals mixing and combining rules. Solid properties were estimated
by different methods available in the literature. The solubilities of several NSAIDs in SCFs, namely in
scCO2, were obtained from the literature and plotted and represented as a function of the corresponding
sublimation pressures and fusion temperatures.
Introduction
Aqueous solubility is one of the key factors affecting the “in
vivo” bioavailability of any drug. However, nearly half of the
substances which were identified as biologically active through
the new paradigm of high-throughput screening are either
insoluble or poorly soluble in water.1 Therefore, the development
of efficient formulations of poorly water-soluble compounds,
aiming to increase in vivo drug bioavailability, represents
nowadays one of the most frequent and greatest challenges for
the pharmaceutical industry.
To improve the bioavailability of poorly water-soluble drugs
as well as to avoid the occurrence of undesired systemic and
nonsystemic side effects due to the use of formulations having
high drug levels, various techniques have been recently proposed
and developed, namely, particle size reduction,2 surfactant-aid
dispersion,3 emulsions and microemulsions,4 solid dispersions,5
etc. But, and like many other traditional pharmaceutical
processes, most of these techniques often require the use of toxic
solvents, with all its negative implications, or the use of high
processing temperatures which may degrade thermally labile
drugs.
Supercritical fluid (SCF) technologies, and in particular
supercritical carbon dioxide (scCO2) based processes, are known
to be new and interesting routes for pharmaceutical processing,
avoiding most of the drawbacks of conventional methods,
particularly those related with the use of toxic organic solvents.6
Furthermore, SCFs present unique properties that may improve
these processes as well as offer innovative possibilities for the
development of new products, with better chemical, physical,
morphological, and mechanical properties and, consequently,
leading to novel and improved final pharmaceutical products.
Micronization of drug particles,7–9 drug-cyclodextrin complex
formation,10,11 and drug impregnation into polymeric matrixes12,13
are some examples of current research strategies to improve
bioavailability of poor water-soluble drugs using supercritical
fluid based technology.
Diflunisal (5-(2,4-difluorophenyl)-2-hydroxy-benzoic acid)
(Figure 1) is a salicylate derivative possessing antipyretic,
analgesic, and anti-inflammatory activities.14 It belongs to the
family of the nonsteroidal anti-inflammatory drugs (NSAIDs),
and it is commonly used to relieve mild to moderate pain and
inflammations caused by arthritis or other inflammatory condi-
tions. Although NSAIDs are among the most frequently used
drugs in the world, their oral administration is often limited
because of their potential to cause adverse effects such as
irritation and ulceration of the gastro-intestinal mucosa.15 These
problems are mainly caused because of the poor water solubility
of these types of drugs. For this reason, considerable efforts
have been made for the development of newer and better
formulations for oral delivery systems of NSAIDs. Some of the
present investigated strategies include also supercritical-based
processes, namely in the field of particle generation using scCO2
technologies, such as rapid expansion of supercritical solutions
(RESS), supercritical anti-solvent (SAS), and particles from gas
saturated solutions (PGSS).7–9
The accurate knowledge of equilibrium solubility of phar-
maceutical products in the employed SCF, at different conditions
of temperature and pressure, is indispensable for the design of
any SCF-based process. This work continues our recent research
activities regarding the preparation of polymeric drug delivery
systems, namely by the use of a supercritical solvent impregna-
tion technique16–22 as well as our previous work on the
experimental determination and correlation of the solubility of
several drugs23–26 and other solid compounds27,28 in scCO2. In
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Figure 1. Chemical structure of diflunisal (5-(2,4-difluorophenyl)-2-
hydroxy-benzoic acid).
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the present work, we present the experimental solubility of
diflunisal in scCO2, at (308.2, 318.2, and 328.2) K and in a
pressure range from (9.0 up to 25.0) MPa, using a static
analytical method. We also present the correlation of the
obtainedexperimentaldatabyusingthewell-knownPeng-Robinson
cubic equation of state with the conventional van der Waals
mixing and combining rules. The solubilities of several NSAIDs
in SCFs, namely, in scCO2, were obtained from literature and
represented as a function of the corresponding sublimation
pressures and fusion temperatures.
Experimental Section
Materials. Carbon dioxide (CAS 124-38-9, purity > 99.998
%) was purchased from Praxair; ethanol (CAS-64-17-5, purity
> 99.5 %) was obtained from Panreac Quimica SA, and
diflunisal (CAS 22494-42-4, 100 % pure) was obtained from
Sigma-Aldrich.
Experimental Procedure. A static phase equilibrium ap-
paratus was used to determine the experimental solubility of
diflunisal in scCO2. A detailed description of this apparatus and
of its validation was given in previous works.27,28 The typical
experimental procedure is described below.
A high-pressure equilibrium cell, equipped with sapphire
windows and with an internal volume of approximately 30 cm3,
is loaded with an excess amount of diflunisal and a magnetic
stirrer. The cell is connected to the apparatus tubing lines and
immersed in a water bath, equipped with a temperature controller
which controls the operational temperature within ( 0.1 K.
Carbon dioxide is liquefied in a cooling unit and compressed
using a high-pressure liquid pump. When the water bath reaches
the experiment temperature, the cell is pressurized with CO2
until the desired experimental pressure is attained. Pressure is
measured with a high-pressure transducer (Setra, model 204,
(0 to 34.40) ( 0.04 MPa). After pressure and tempera-
ture stabilization, the magnetic stirring plate, positioned under
the equilibrium cell, is switched on and the diflunisal + CO2
mixture is left to stir for one hour (the period of time found to
be necessary to attain equilibrium and complete fluid phase
saturation), followed by a 20 min period, without stirring, to
allow mixture stabilization. A homogeneous mixture sample is
then removed from the cell, using a six-port sampling valve
(Rheodyne, model 7060), into a sampling loop of 0.456 cm3.
This sample is then quickly depressurized and expanded into
previously calibrated volumes, which are composed by a glass
trap (15.9 cm3), immersed in ice, and a stainless steel balloon
(1735.05 cm3), immersed in a water bath at room temperature
and previously brought into subatmospheric pressure using a
vacuum pump. The resulting pressure increase is then measured
using a calibrated high-precision low-pressure transducer (Setra,
model 204, (0 to 0.175) ( 1.9 ·10-4 MPa). During expansion,
the formerly dissolved solid precipitates in the glass trap. To
recover all the precipitated solid, a cleaning solvent (ethanol)
is injected through the sample loop and expansion lines and
recollected in the glass trap. The lines are also cleaned with
fresh CO2 smoothly pressurized.
The amount of solubilized solid was determined by UV
spectrophotometric analysis. Collected samples containing the
solid are diluted to a convenient volume with ethanol, and the
absorbance of the resulting solutions is measured at a fixed
wavelength (254 nm) using a UV/vis spectrophotometer (JAS-
CO V-530). A calibration curve was obtained by UV analysis
of previously prepared standard solid samples. The amount of
CO2 in the sample loop is calculated using the Virial EOS
(applied to pure CO2) and considering the values of the
precalibrated expansion volumes, the resulting subatmospheric
pressure increase due to expansion, the temperature of the water
bath where the expansion balloon is immersed, and the
temperature of the ice-immersed glass trap (which is considered
to be 273.15 K).
Each experimental solubility data point is the average of, at
least, three replicate measurements. The relative standard
deviation values were taken as an indication of replicate
measurement reproducibility. The overall uncertainty, taking into
consideration the random uncertainties (statistical, associated
to Beer-Lambert’s calibration curve and to the average of the
experimental solubility measurements) and the systematic
uncertainties (uncertainties due to the preparation of standard
calibration solutions and to pressure and temperature measure-
ments), was found to be less than 1.1 ·10-6 (in terms of diflunisal
mole fraction).
EOS Correlation of Experimental Solubility Data. Usually,
in solid-SCF phase equilibria, the supercritical phase is treated
as a compressed gas phase, and the solid solubility is then given
Table 1. Experimental Solubility of Diflunisal in Supercritical
Carbon Dioxide
T ) 308.2 K T ) 318.2 K T ) 328.2 K
P/MPa (y2 ( SD) ·106 P/MPa (y2 ( SD) ·106 P/MPa (y2 ( SD) ·106
9.4 1.845 ( 0.078 9.3 0.565 ( 0.045 9.1 0.544 ( 0.082
11.8 1.959 ( 0.283 11.6 1.212 ( 0.064 11.6 0.899 ( 0.087
14.2 2.060 ( 0.264 14.2 1.701 ( 0.186 14.2 1.730 ( 0.123
16.8 2.268 ( 0.242 17.0 3.143 ( 0.371 16.8 3.603 ( 0.042
19.5 2.675 ( 0.134 19.3 3.923 ( 0.320 19.3 4.593 ( 0.094
21.9 2.980 ( 0.192 21.9 4.497 ( 0.134 21.9 6.625 ( 0.177
24.6 3.892 ( 0.353 24.4 5.466 ( 0.260 24.4 8.072 ( 0.395
Table 2. Estimated Critical and Thermophysical Properties of
Diflunisal
104 ·P2sub/Pa
Tc/K Pc/MPa ω 106 · V2/m3 ·mol-1 308.2 K 318.2 K 328.2 K
869.8a 3.211a 0.897a 125.5b 0.33c 1.42c 5.63c
a Estimated by the Constantinou-Gani (first order) method.30
b Estimated by the Fedors method.31 c Extrapolated from data presented
by Perlovich et al.32
Table 3. Correlation Results Obtained with the PR-EOS Model
PR-EOS
T/K mixing rule k12 l12 AARD (%)
308.2 vdW1 0.173 19.2
vdW2 0.140 -0.081 17.3
318.2 vdW1 0.169 20.5
vdW2 0.194 0.070 20.6
328.2 vdW1 0.164 23.9
vdW2 0.190 -0.071 23.3
Figure 2. Solubility of diflunisal in scCO2. Experimental: 2, 308.2 K; ],
318.2 K; and 9, 328.2 K. s, Correlated with the PR-vdW2 model.
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by an expression derived from the thermodynamic equilibrium
conditions between the solid phase and that high-pressure gas
phase.
Thus, the solubility of a solid solute (y2), in equilibrium with








SCF exp[V2(P-P2sub)RT ] (1)
This equation is derived from the equifugacity condition
between the solid and the fluid phase, under the assumptions
that the solubility of the solvent (scCO2) in the solid phase is
negligible, that the solid is incompressible, and that the saturated
vapor of the pure solid solute at sublimation behaves like an
ideal gas. In eq 1, P is the pressure; P2sub is the sublimation
pressure of the pure solid (at temperature T); V2 is the molar
volume of the solid; and 
2
SCF
, is the solid fugacity coefficient
in the high-pressure fluid phase, which expresses the nonideality
of the fluid phase. This parameter is usually evaluated by an
EOS, and cubic EOSs are the most widely used models to
evaluate the fugacity coefficients of solids in compressed fluid
phases. In this work, the well-known Peng-Robinson cubic
equation of state29 (PR-EOS) was employed to evaluate the




V(V+ b)+ b(V- b) (2)
a) 0.45724(R2Tc2Pc ){1+ n[1- ( TTc)0.5]}2 (3)





To apply the above EOS model for a binary solid + scCO2
system, we employed the classical van der Waals (vdW) mixing
and combining rules, with one or with two adjustable param-











aij ) (aiiajj)0.5(1- kij) (8)
bij ) (bii + bjj2 )(1- lij) (9)
The optimal binary interaction parameters, kij and lij, for each
temperature must be obtained by the correlation of experimental
data, through the minimization of the objective function average






In this equation, N is the number of experimental data points
for each temperature; ycalcd corresponds to the calculated
solubilities; and yexptl corresponds to the experimental solubility
data points.
As can be seen, the PR-EOS model always need informa-
tion concerning the critical properties and the Pitzer’s acentric
factors of all involved compounds as well as the molar
volume and the sublimation pressure of the studied solid.
However, and for most organic solids (like NSAIDs and other
common drugs), these properties are usually unknown and
difficult, or even impossible, to obtain. This represents a well-
known disadvantage for the application of cubic EOS
correlation models. Thus, the required solid properties are
normally obtained using group contribution estimation meth-
ods or other estimation methods that can be found in the
literature. For practical reasons, the majority of these
estimation methods was developed based on the behavior of
pure components that are gases or liquids at normal temper-
ature and pressure (which is not the case in most situations).
An excellent review on the most important estimation
methods for these properties can be found in the recent book
by Poling, Prausnitz, and O’Connell30 as well as on its
previous editions. On previous works, we already discussed
the applicability of several of these property estimation
methods26,28 and referred that these should be selected and
employed very carefully. Furthermore, and without any
reliable experimental sublimation pressure data, special
attention should be paid to this property because it is
recognized to be a key property to achieve successful EOS-
based correlation results.28
In this work, diflunisal critical properties and acentric factors
were estimated using the Constantinou-Gani (first order)
method.30 Solid molar volume was estimated using the Fedors
method.31 Diflunisal sublimation pressures, at (308.2, 318.2, and
328.2) K, were extrapolated from the Clausius-Clapeyron
equation presented by Perlovich et al.,32 which was derived from
experimental sublimation pressures measured between (349 and
410) K.
Results and Discussion
The experimental mole fraction solubilities of diflunisal in
scCO2 were obtained at (308.2, 318.2, and 328.2) K, in a
pressure range from (9.0 up to 25.0) MPa, and are reported in
Table 1. The obtained diflunisal solubility values (y2) varied
between 0.54 ·10-6 and 8.07 ·10-6 and, as referred to in the
Experimental Section, each reported data point is the average
of at least three replicate experimental measurements.
The relative standard deviation (RSD) values were taken as
an indication of replicate measurement reproducibility and varied
between 15.1 % (T ) 328.2 K, P ) 9.1 MPa) and 2 % (T )
328.2 K, P ) 19.3 MPa). In general terms and as usually found
in the literature for this type of measurements, the experimental
points presenting higher values of RSD were those obtained at
lower experimental pressures, which correspond to the lower
solid solubility values.
The values of the required critical and thermophysical
properties for the PR-EOS correlation of diflunisal solubility
in scCO2 are presented in Table 2.
The optimal fitted binary interaction parameters and the
corresponding AARD values, which were obtained by the
correlation of experimental solubility data with the PR-EOS
model and using the set of properties indicated in Table 2, are
presented in Table 3. The vdW mixing and combining rules
with one adjustable parameter (PR-vdW1) or with two adjustable
parameters (PR-vdW2) were employed.
As can be seen, the applied models were able to correlate
the experimental data, however yielding AARD values around
20 %. Notably, the model with only one fitted parameter (PR-
vdW1) demonstrated a similar capacity to correlate the
obtained experimental data as the model with two fitted
parameters (PR-vdW2). From our previous experience25–28
in the correlation of solid/scCO2 solubility data with cubic
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equations of state, like the PR-EOS and the Soave-Redlich-
Kwong (SRK) EOS, and using the vdW mixing and com-
bining rules, we found that usually a model with two
adjustable parameters is required to successfully fit experi-
mental solubility points in the whole pressure range, espe-
cially at higher pressures, the model with only one adjustable
parameter being unable to do that.
In these works, we also noticed that the solid sublimation
pressure plays, among all the input properties, a dominant
role in the ability of a cubic EOS model to correlate
experimental solubility data, especially when only one
adjustable parameter is used. Previously, other authors
reached the same conclusion.33,34 Unfortunately, and for the
majority of low volatile solids, this property is usually
unknown and is often calculated by empirical correlations
or by extrapolation of experimental data at different pressure
and temperature conditions which, in some cases, may lead
to doubtful estimations. Moreover, and mainly for this reason,
a different strategy which considers the sublimation pressure
as an adjustable parameter, together with the binary interac-
tion parameters, can also be employed.26,35,36
In this work, the employed values of diflunisal sublimation
pressure were obtained based on diflunisal experimental sub-
limation pressure data, and this fact can explain the observed
good fitting results achieved even with the one adjustable
parameter model (PR-vdW1). Once again, this evidences the
importance of having reasonably accurate sublimation pressure
values when using these types of EOS models for the correlation
of solid solubility experimental data.
In Figure 2, the experimental solubility of diflunisal in
scCO2 is represented as a function of pressure, for the three
studied isotherms. The corresponding correlation curves
(obtained with the PR-vdW2 model) are also shown. As can
be seen, higher deviations are observed for lower pressures
and for lower isotherms. Furthermore, for the results at 308.2
K, the correlation curve is far from fitting the experimental
points. The typical retrograde solubility behavior of the solid
is also present at this system. This phenomenon is well-known
for most solid + SCFs systems, and it is caused by the
opposite effect of temperature on the density of the SCF and
on the solid sublimation pressure. For this system, the so-
called cross-over region, where one can observe the intersec-
tion of the solubility isotherms and where below this point
an isobaric increase in temperature corresponds to a solubility
decrease, is located around 15.0 MPa.
Due to their widely spread use, NSAIDs have been the
subject of many research works, namely on the field of
pharmaceutical formulations, in which scientists face the
challenge of developing better and safer formulations for
these inherently poor water-soluble class of drugs. And, as
mentioned, the use of supercritical processes to overcome
these issues has also been under intense investigation.
Therefore, the solubility of many of these drugs in SCFs,
namely in scCO2, has been quite studied. Table 4 displays a
collection of the experimental solubilities (in scCO2) of some
of the most important NSAIDs. Solubility is expressed in
terms of mole fraction solubilities of these drugs. The
experimental values of the corresponding fusion temperatures
(Tf) and of sublimation pressures (Psub) are also presented
in this table. All these experimental values were obtained
from the literature.
In Figure 3, the logarithms of the solubilities of these drugs
(at approximately 20 MPa and at (40 to 45) °C) are plotted
against the corresponding sublimation pressures (Figure 3a) and
against fusion temperatures (Figure 3b).
As can be seen in Figure 3a, the logarithms of the solubilities
of these NSAIDs present an increasing tendency with the
matching sublimation pressures. On the other hand, in Figure
3b, it is also possible to observe an overall decreasing trend
Table 4. Fusion Temperature, Sublimation Pressure, and Experimental Solubility in scCO2 of Some NSAIDs
solubility in scCO2
drug formula Tf (°C) Pa (Pa) T (°C) P (MPa) y2
ACET C8H9NO2 168 to 172 Exp[34.3 to 14010/T(K)]a 40 10 to 25 (0.4 to 1.8) ·10-6g
ASAL Ac C9H8O4 138 to 140 Exp[38.2 to 13190/T(K)]b 45 12 to 25 (0.7 to 2.6) ·10-4h
DIF C13H8F2O3 219 to 220 Exp[36.4 to 14400/T(K)]c 45 10 to 25 (0.6 to 5.5) ·10-6i
FLU C15H13O2 110 to 112 Exp[33.8 to 13040/T(K)]c 40 10 to 24 (0.2 to 1.5) ·10-4j
IBU C13H18O2 73 to 76 Exp[40.4 to 13927/T(K)]d 40 10 to 22 (0.5 to 6.4) ·10-3k
KET C16H14O3 93 to 94 Exp[33.0 to 13250/T(K)]e 40 9 to 25 (0.4 to 9.2) ·10-5l
NAP C14H14O3 153 to 154 Exp[39.7 to 15431/T(K)]f 40 9 to 19 (0.2 to 2.4) ·10-5m
a Ref 37. b Ref 38. c Ref 32. d Ref 39. e Ref 40. f Ref 41. g Ref 42. h Ref 43. i This work. j Ref 23. k Ref 44. l Ref 45. m Ref 46. Ibuprofen (IBU),
acetylsalicylic acid (ASAL Ac), flurbiprofen (FLU), ketoprofen (KET), naproxen (NAP), diflunisal (DIF), acetaminophen (ACET).
Figure 3. Solubility of several NSAIDs in scCO2, at (40 to 45) °C and at
approximately 20 MPa, plotted against: (a) sublimation pressure; (b) fusion
temperature (Tf). Ibuprofen (IBU), acetylsalicylic acid (ASAL Ac), flurbi-
profen (FLU), ketoprofen (KET), naproxen (NAP), diflunisal (DIF), and
acetaminophen (ACET).
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between the NSAID logarithms of solubilities and their fusion
temperatures. These general trends were expected since it is
well established that the solubility of a solid in a pure SCF,
like CO2, is mainly determined by the SCF density and the by
the volatility of the solid which is always dependent on
properties such as solid sublimation pressure and solid fusion
temperature.
Conclusions
The experimental solubility of diflunisal in scCO2 was
measured at (308.2, 318.2, and 328.2) K and in a pressure range
from (9.0 up to 25.0) MPa, using a static analytical method.
The obtained experimental solubility data were successfully
correlated by the Peng-Robinson cubic EOS and using the
classical van der Waals mixing rules, with one or with two
adjustable parameters.
The solubilities of several NSAIDs in SCFs, namely in scCO2,
were obtained from the literature and plotted and represented
as a function of the corresponding sublimation pressures and
fusion temperatures.
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